Sun Pharma Corporate Overview

Key Deals & Rationale Year Deals Country Rationale SUN PHARMA Middle 2020 Exclusive licensing agreement with Himka for Ilumya East & North Africa 2020 Licensing agreement with SPARC for SCD-044 Global Registration and commercialization of the product in all Middle East & North Africa (MENA) markets. Potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders 2020 In-licensed Triferic brand from Rockwell Medical Inc. (USA) India Expands nephrology portfolio in India for treating anaemia in hemodialysis patients. - 2019 Licensing agreement with Astrazeneca UK for ready-to-use infusion oncology products Mainland China Access to oncology market in Mainland China Licensing agreement with CMS for Greater 2019 Tildrakizumab, Cequa & 8 generic Access to Greater China market China products 2018 Acquired Pola Pharma in Japan Japan Access to Japanese dermatology market. 2016 Acquired global rights for Cequa & Odomzo Global Enhances specialty pipeline. 2016 Acquired Biosintez Russia Local manufacturing capability to enhance presence in Russian market 2016 Licensing agreement with Almirall for Tildrakizumab for Psoriasis Europe Access to European market for Tidrakizumab © Sun Pharmaceutical Industries Limited. All Rights Reserved. 15 S

View entire presentation